Form 4: Humana Director Acquires 766 Restricted Stock Units

Humana Inc. Director Jorge S. Mesquita acquired 766 restricted stock units, increasing his indirect beneficial ownership to 4,127 shares.

Summary

• Jorge S. Mesquita, a Director of Humana Inc., acquired 766 shares of Humana Common Stock.
• The acquisition occurred on January 2, 2026.
• These shares are restricted stock units (RSUs) granted at a price of $0.
• Following this transaction, Mesquita indirectly beneficially owns a total of 4,127 shares.
• The RSUs represent a contingent right to receive one share of Humana Inc. common stock and are exempt under Rule 16b-3(d)(1)&(3) of the Company's 2019 Amended & Restated Plan.
• The shares are held in a Revocable Trust where Mesquita is the sole trustee, established on March 10, 2003.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director is generally a positive signal, indicating continued alignment of interests with the company's long-term performance. It's a routine compensation event rather than a significant market-moving announcement.

Positives

• A Director, Jorge S. Mesquita, increased his beneficial ownership in Humana Inc. by acquiring 766 restricted stock units.
• The acquisition of restricted stock units at a $0 price indicates a grant, which is a common incentive to align management interests with shareholders for long-term performance.

Risks

• The value of the restricted stock units is contingent on future vesting conditions and the market performance of Humana Inc.'s common stock.

Future Outlook

The acquisition of restricted stock units suggests a long-term incentive for the director, aligning future compensation with company performance and shareholder value, as these units typically vest over time and are tied to the company's stock price.

Industry Context

Insider transactions, particularly grants of restricted stock units to directors, are common practices in the healthcare insurance industry to incentivize long-term commitment and align leadership interests with company performance and shareholder returns. This aligns with standard corporate governance practices aimed at fostering executive retention and performance.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard compensation practice across publicly traded companies, including those in the healthcare sector like UnitedHealth Group (UNH) or Elevance Health (ELV).
• The $0 acquisition price is typical for such grants, which vest over time and are designed to align the recipient's financial interests with the company's stock performance.

Stakeholder Impact

• Shareholders: Potentially positive as the director's interests are further aligned with the company's long-term performance and stock value.

Next Steps

• The restricted stock units will vest according to the terms and schedule outlined in Humana Inc.'s 2019 Amended & Restated Plan.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to a director, which is a standard compensation practice. While it indicates continued alignment of management interests with shareholders, it does not present new information that would fundamentally alter the investment thesis for Humana Inc. Therefore, a 'hold' recommendation is appropriate as it doesn't provide a strong catalyst for either buying or selling.

Keywords

Humana Inc., HUM, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director, Stock Grant, Beneficial Ownership